盐酸纳呋拉啡口崩片在中国上市:为CKD和血液透析患者提供新的瘙痒治疗选择

Introduction: Nafurafine hydrochloride orally disintegrating tablets will be launched in China on September 13, 2023, for the treatment of uremic pruritus in patients with chronic kidney disease and receiving hemodialysis. Nafurafine hydrochloride orally disintegrating tablets are potent, selective and centrally active and are the first selective KOR agonist approved for clinical use.

Nafuraphine Hydrochloride Orally Disintegrating Tablets China Marketing Information

It was developed by a Japanese pharmaceutical company and has been approved for marketing by the National Medical Products Administration (NMPA) of China. The specific launch date is September 13, 2023, and the approval number is "National Drug Approval Number HJ20230091".

Medical insurance information of Nafurafine Hydrochloride Orally Disintegrating Tablets

Nafurafine Hydrochloride Orally Disintegrating Tablets have been included in China’s National Reimbursement Catalog, which means that eligible patients can enjoy medical insurance reimbursement when using this drug, reducing the burden of medical expenses. However, the specific reimbursement ratio varies depending on factors such as region, type of medical insurance, and patient's personal medical insurance status.

Generally speaking, the medical insurance reimbursement ratio will be set based on factors such as drug classification, medical institution level, and personal medical insurance account balance, and may be between a certain percentage. For example, some cities may stipulate that the reimbursement ratio is 70% to 90%. For specific values, refer to local medical insurance policies or consult the medical insurance agency. Some areas may also have medical insurance payment limits or annual caps, and the patient may have to pay for any excess above the limits.

The medical insurance purchase process of Nafurafine Hydrochloride Orally Disintegrating Tablets

To use Nafurafine Hydrochloride Orally Disintegrating Tablets for treatment, patients first need to go to medical insurance designated medical institutions, such as public hospitals, some private hospitals or community health service centers, and receive a prescription. Your doctor will prescribe nalfuraphine hydrochloride orally disintegrating tablets based on your condition. The patient takes the prescription to the medical insurance settlement window of the medical institution or a designated pharmacy for medical insurance settlement, submits the medical insurance card or electronic medical insurance voucher, and enjoys medical insurance reimbursement according to the prescribed reimbursement ratio. It should be noted that some medical insurance policies may require patients to pay a certain proportion of expenses out of pocket first (such as a deductible), and only after reaching the deductible can they enjoy medical insurance reimbursement.

Precautions for Nafurafine Hydrochloride Orally Disintegrating Tablets

Patients should pay attention when taking Nafurafine Hydrochloride Orally Disintegrating Tablets. This drug is an orally disintegrating tablet and does not need to be swallowed with water. The correct way to use it is to place the tablet on the tongue, let it dissolve quickly in the mouth, and then swallow the dissolved medicine. During treatment, attention should be paid to observing possible side effects of the drug, such as dizziness, insomnia, constipation, nausea, vomiting, etc. If the side effects are severe, the drug should be discontinued in time and seek medical treatment offline.